Synlogic (NASDAQ:SYBX) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09, Fidelity Earnings reports. Synlogic had a negative net margin of 1,844.96% and a negative return on equity of 34.75%. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.46 million.
NASDAQ SYBX traded up $0.10 on Wednesday, reaching $2.32. 207,000 shares of the company’s stock traded hands, compared to its average volume of 144,962. The company has a debt-to-equity ratio of 0.13, a current ratio of 14.43 and a quick ratio of 14.43. Synlogic has a 12 month low of $1.96 and a 12 month high of $11.43. The stock has a market cap of $72.64 million, a PE ratio of -1.14 and a beta of 2.56. The stock has a 50-day simple moving average of $2.19 and a 200 day simple moving average of $5.37.
A number of research analysts have commented on SYBX shares. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Synlogic in a research report on Monday, September 9th. Wedbush reiterated an “outperform” rating and set a $20.00 price target on shares of Synlogic in a research report on Friday, August 9th. ValuEngine upgraded shares of Synlogic from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Citigroup cut shares of Synlogic from a “buy” rating to a “sell” rating and reduced their price target for the company from $20.00 to $2.00 in a research report on Wednesday, August 21st. Finally, Oppenheimer cut shares of Synlogic from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. Synlogic presently has a consensus rating of “Buy” and an average target price of $13.69.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Further Reading: What are the reasons investors use put options?
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.